Trial Profile
Phase I Trial of Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Cisplatin; Gemcitabine
- Indications Urogenital cancer
- Focus Adverse reactions
- 29 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 14 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 29 Apr 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016, according to ClinicalTrials.gov record.